Poland· PL-100429680

Quofenix

A delafloxacin product containing delafloxacini megluminum, registered in Poland by A. Menarini - Industrie Farmaceutiche Riunite – s.r.l.. The same ATC class is registered in 10 of our 19 countries.

ATC J01MA23

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedQuofenixATCJ01MA23REGISTER NO.PL-100429680PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Delafloxacin is registered in 10 of 19 countries.

Countries holding a registration under ATC J01MA23 (delafloxacin), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 6 of them publish a price we can compare per daily dose

Delafloxacin · ATC J01MA23

10 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of delafloxacin costs, country by country.

Normalised to the WHO defined daily dose (0.9 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Delafloxacin · price per daily dose (0.9 g)

USD · FX 28 Sept 2026

  • CH Switzerland$210.37
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Delafloxacini megluminum
Manufacturer
A. Menarini - Industrie Farmaceutiche Riunite – s.r.l.
Country
Poland (PL)
ATC code
J01MA23
ATC class
Delafloxacin
Defined daily dose
0.9 g, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    08059591080085

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

222 interactions on record for delafloxacin.

Graded by severity as the source publishes them — 44 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Delafloxacin · interactions on record

222 records

  • 44 severe
  • 125 moderate
  • 53 minor

Most severe, free to view

  • PrednisoloneA07EA01severe
  • HydrocortisoneA07EA02severe
  • PrednisoneA07EA03severe
  • BetamethasoneA07EA04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/885264bc-6cf9-484f-b193-2926d85e91e0
GET /v1/drugs/885264bc-6cf9-484f-b193-2926d85e91e0?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Proszek do sporządzania koncentratu roztworu do infuzji",
  "source": "urpl",
  "strength": "300 mg",
  "packaging": "08059591080085 ¦ Rp ¦ EU/1/19/1393/001 ¦ 135069\n10 fiol.",
  "substance": "Delafloxacini megluminum 300 mg",
  "common_name": "Delafloxacini megluminum",
  "pl_product_id": "100429680",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}

See everything about delafloxacin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.